The effects of lorazepam on extrastriatal dopamine D2/3-receptors-A double-blind randomized placebo-controlled PET study

Psychiatry Research - Neuroimaging

Volumn 174, Issue 2, 2009, Pages 130-137

  Vilkman, Harry ^a   Kajander, Jaana ^a   Aalto, Sargo ^a,b   Vahlberg, Tero ^a   Någren, Kjell ^c   Allonen, Topias ^a   Syvälahti, Erkka ^a   Hietala, Jarmo ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b ÅBO AKADEMI UNIVERSITY   (Finland)

^c TURKU PET CENTRE   (Finland)

Author keywords

Benzodiazepines; Dopamine; Dopamine D2 receptor; GABA A receptor; Positron Emission Tomography

Indexed keywords

CARBON 11; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; ISOREMOXIPRIDE; LORAZEPAM; PLACEBO;

ADULT; ARTICLE; BRAIN CORTEX; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RECEPTOR BINDING; HUMAN; HUMAN EXPERIMENT; MALE; NEUROIMAGING; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SINGLE DRUG DOSE; THALAMUS;

ADULT; ANALYSIS OF VARIANCE; BRAIN MAPPING; CARBON ISOTOPES; CEREBRAL CORTEX; DOPAMINE ANTAGONISTS; DOUBLE-BLIND METHOD; GABA MODULATORS; HUMANS; LORAZEPAM; MALE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PYRROLIDINES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SALICYLAMIDES; THALAMUS; TIME FACTORS; YOUNG ADULT;

EID: 71849083641     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2009.04.006     Document Type: Article

References (70)

1. Aalto S., Ihalainen J., Hirvonen J., Kajander J., Scheinin H., Tanila H., Någren K., Vilkman H., Gustafsson L.L., Syvälahti E., and Hietala J. Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology 182 (2005) 375-383
2. Aalto S., Brück A., Laine M., Någren K., and Rinne J.O. Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457. Journal of Neuroscience 25 (2005) 2471-2477
3. Aalto S., Hirvonen J., Kaasinen V., Hagelberg N., Kajander J., Någren K., Seppälä T., Rinne J.O., Scheinin H., and Hietala J. The effects of d-amphetamine on extrastriatal dopamine D(2)/D(3) receptors: a randomized, double-blind, placebo controlled PET study with [(11)C]FLB 457 in healthy subjects. European Journal of Nuclear Medicine and Molecular Imaging 36 (2009) 475-483
4. Aquilonius S.-M., and Eckernäs S.-Å. A Colour Atlas of the Human Brain (1980), Esselte studium, Stockholm, Sweden
5. Bentué-Ferrer D., Reymann J.M., Tribut O., Allain H., Vasar E., and Bourin M. Role of dopaminergic and serotonergic systems on behavioral stimulatory effects of low-dose alprazolam and lorazepam. European Neuropsychopharmacology 11 (2001) 41-50
6. Biggio G., Concas A., Corda M.G., Giorgi O., Sanna E., and Serra M. GABAergic and dopaminergic transmission in the rat cerebral cortex: effect of stress, anxiolytic and anxiogenic drugs. Pharmacology & Therapeutics 48 (1990) 121-142
7. Blomqvist G. On the construction of functional maps in positron emission tomography. Journal of Cerebral Blood Flow and Metabolism 4 (1984) 629-632
8. Brose N., O'Neill R.D., Boutelle M.G., and Fillenz M. Dopamine in the basal ganglia and benzodiazepine-induced sedation. Neuropharmacology 27 (1988) 589-595
9. Bunney B.S., and Aghajanian G.K. Dopaminergic influence in the basal ganglia: evidence for striatonigral feedback regulation. Research Publications - Association for Research in Nervous and Mental Disease 55 (1976) 249-267
10. Busatto G.F., Pilowsky L.S., Costa D.C., Ell P.J., David A.S., Lucey J.V., and Kerwin R.W. Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. American Journal of Psychiatry 154 (1997) 56-63
11. Chou Y.H., Karlsson P., Halldin C., Olsson H., and Farde L. A PET study of D(1)-like dopamine receptor ligand binding during altered endogenous dopamine levels in the primate brain. Psychopharmacology 146 (1999) 220-227
12. Chou Y.H., Halldin C., and Farde L. Effect of amphetamine on extrastriatal D2 dopamine receptor binding in the primate brain: a PET study. Synapse 38 (2000) 138-143
13. Chugani D.C., Ackermann R.F., and Phelps M.E. In vivo [3H]Spiperone binding: evidence for accumulation in corpus striatum by agonist-mediated receptor internalization. Journal of Cerebral Blood Flow and Metabolism 8 (1988) 291-303
14. Dazzi L., Motzo C., Imperato A., Serra M., Gessa G.L., and Biggio G. Modulation of basal and stress-induced release of acetylcholine and dopamine in rat brain by abecarnil and imidazenil, two anxioselective gamma-aminobutyric acid-A receptor modulators. Journal of Pharmacology and Experimental Therapeutics 273 (1995) 241-247
15. Del Arco A., and Mora F. Prefrontal cortex-nucleus accumbens interaction: in vivo modulation by dopamine and glutamate in the prefrontal cortex. Pharmacology, Biochemistry and Behavior 90 (2008) 226-235
16. Dewey S.L., Smith G.S., Logan J., Brodie J.D., Yu D.W., Ferrieri R.A., King P.T., MacGregor R.R., Martin T.P., Wolf A.P., Volkow N.D., Fowler J.S., and Meller E. GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-raclopride and positron emission tomography. Journal of Neuroscience 12 (1992) 3773-3780
17. Di Chiara G., Porceddu M.L., Vargiu L., Argiolas A., and Gessa G.L. Evidence for dopamine receptors mediating sedation in the mouse brain. Nature 264 (1976) 564-567
18. Farde L., Suhara T., Nyberg S., Karlsson P., Nakashima Y., Hietala J., and Halldin C. A PET-study of [C-11]FLB 457 binding to extrastriatal D-2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology 133 (1997) 396-404
19. Feenstra M.G.P., Bottenblom M.H.A., and van Uum J.F.M. Novelty-induced increase in dopamine in the rat prefrontal cortex in vivo: inhibition by diazepam. Neuroscience Letters 189 (1995) 81-84
20. Finlay J.M., Zigmond M.J., and Abercrombie E.D. Increased dopamine and norepinephrine release in medial prefrontal cortex induced by acute and chronic stress: effects of diazepam. Neuroscience 64 (1995) 619-628
21. Frankle W.G., Laruelle M., and Haber S.N. Prefrontal cortical projections to the midbrain in primates: evidence for a sparse connection. Neuropsychopharmacology 31 (2006) 1627-1636
22. Friston K.J., Holmes A.P., Worsley K.J., Poline J.P., Frith C.D., and Frackowiak R.S. Statistical parametric maps in functional imaging: a general linear approach. Human Brain Mapping 2 (1995) 189-210
23. Fujita M., Verhoeff N.P.L.G., Varrone A., Zoghbi S.S., Baldwin R.M., Jatlow P.A., Anderson G.M., Seibyl J.P., and Innis R.B. Imaging extrastriatal dopamine D(2) receptor occupancy by endogenous dopamine in healthy humans. European Journal of Pharmacology 387 (2000) 179-188
24. Gifkins A., Greba Q., and Kokkinidis L. Ventral tegmental area dopamine neurons mediate the shock sensitization of acoustic startle: a potential site of action for benzodiazepine anxiolytics. Behavioral Neuroscience 116 (2002) 785-794
25. Gottesmann C. The neurochemistry of waking and sleeping mental activity: the disinhibition dopamine hypothesis. Psychiatry and Clinical Neurosciences 56 (2002) 345-354
26. Greenblatt D.J. Clinical pharmacokinetics of oxazepam and lorazepam. Clinical Pharmacokinetics 6 (1981) 89-105
27. Greenblatt D.J., Shader R.I., Franke K., MacLaughlin D.S., Harmatz J.S., Allen M.D., Werner A., and Woo E. Pharmacokinetics and bioavailability of intravenous, intramuscular and oral lorazepam in humans. Journal of Pharmaceutical Sciences 68 (1979) 57-63
28. Gunn R.N., Lammertsma A.A., Hume S.P., and Cunningham V.J. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. NeuroImage 6 (1997) 279-287
29. Hagelberg N., Aalto S., Kajander J., Oikonen V., Hinkka S., Någren K., Hietala J., and Scheinin H. Alfentanil increases dopamine D2/D3 receptor binding in healthy subjects. Pain 109 (2004) 86-93
30. Halldin C., Farde L., Högberg T., Mohell N., Hall H., Suhara T., Karlsson P., Nakashima Y., and Swahn C.G. Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. Journal of Nuclear Medicine 36 (1995) 1275-1281
31. Hegarty A.A., and Vogel W.H. The effect of acute and chronic diazepam treatment on stress-induced changes in cortical dopamine in the rat. Pharmacology, Biochemistry, and Behavior 52 (1995) 771-778
32. Hietala J., Kuoppamäki M., Någren K., Lehikoinen P., and Syvälahti E. Effects of lorazepam administration on striatal dopamine D2 receptor binding characteristics in man - a positron emission tomography study. Psychopharmacology 132 (1997) 361-365
33. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., Holden J., Houle S., Huang S.-C., Ichise M., Iida H., Ito H., Kimura Y., Koeppe R.A., Knudsen G.M., Knuuti J., Lammertsma A.A., Laruelle M., Logan J., Maguire R.P., Mintun M.A., Morris E.D., Parsey R., Price J.C., Slifstein M., Sossi V., Suhara T., Votaw J.R., Wong D.F., and Carlson R.E. Consensus nomenclature for in vivo imaging of reversible binding radioligands. Journal of Cerebral Blood Flow and Metabolism 27 (2007) 1533-1539
34. Joel D., and Weiner I. The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 96 (2000) 451-474
35. Kalivas P.W. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Research. Brain Research Reviews 18 (1993) 75-113
36. Kubota Y., Inagaki S., Kito S., and Wu J.Y. Dopaminergic axons directly make synapses with GABAergic neurons in the rat neostriatum. Brain Research 406 (1987) 147-156
37. Lammertsma A.A., and Hume S.P. Simplified reference tissue model for PET receptor studies. NeuroImage 4 (1996) 153-158
38. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. Journal of Cerebral Blood Flow and Metabolism 20 (2000) 423-451
39. Lawson C.L., and Hanson R.J. Solving Least Squares Problems (1974), Prentice-Hall, New Jersey
40. Levy F. Pharmacological and therapeutic directions in ADHD: specificity in the PFC. Behavioral and Brain Functions 4 (2008) 12 10.1186/1744-9081-4-12 (e-pub)
41. Lokwan S.J., Overton P.G., Berry M.S., and Clark D. The medial prefrontal cortex plays an important role in the excitation of A10 dopaminergic neurons following intravenous muscimol administration. Neuroscience 95 (2000) 647-656
42. Lorr M., and Wunderlich R.A. A semantic differential mood scale. Journal of Clinical Psychology 44 (1988) 33-36
43. Lorr M., McNair D.M., and Fisher S.U. Evidence for bipolar mood states. Journal of Personality Assessment 46 (1982) 432-436
44. Lynd-Balta E., and Haber S.N. The organization of midbrain projections to the striatum in the primate: sensorimotor-related striatum versus ventral striatum. Neuroscience 59 (1994) 625-640
45. Maj J., Przewlocka B., and Kukulka L. Sedative action of low doses of dopaminergic agents. Polish Journal of Pharmacology and Pharmacy 29 (1977) 11-21
46. Malizia A.L., Cunningham V.J., Bell C.J., Liddle P.F., Jones T., and Nutt D.J. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Archives of General Psychiatry 55 (1998) 715-720
47. Matthew E., Andreason P., Pettigrew K., Carson R.E., Herscovitch P., Cohen R., King C., Johanson C.-E., Greenblatt D.J., and Paul S.M. Benzodiazepine receptors mediate regional blood flow changes in the living human brain. Proceedings of the National Academy of Sciences of the United States of America 92 (1995) 2775-2779
48. McRitchie D.A., Cartwright H., Pond S.M., van der Schyf C.J., Castagnoli Jr. N., van der Nest D.G., and Halliday G.M. The midbrain dopaminergic cell groups in the baboon Papio ursinus. Brain Research Bulletin 47 (1998) 611-623
49. Mehta A.K., and Ticku M.K. An update on GABA-A receptors. Brain Research. Brain Research Reviews 29 (1999) 196-217
50. Montgomery A.J., Asselin M.C., Farde L., and Grasby P.M. Measurement of methylphenidate-induced change in extrastriatal dopamine concentration using [11C]FLB 457 PET. Journal of Cerebral Blood Flow and Metabolism 27 (2007) 369-377
51. O'Brien D.P., and White F.J. Inhibition of non-dopamine cells in the ventral tegmental area by benzodiazepines: relationship to A10 dopamine cell activity. European Journal of Pharmacology 142 (1987) 343-354
52. O'Dowd B.F., Ji X., Alijaniaram M., Rajaram R.D., Kong M.M., Rashid A., Nguyen T., and George S.R. Dopamine receptor oligomerization visualized in living cells. Journal of Biological Chemistry 280 (2005) 37225-37235
53. Olsson H., Halldin C., Swahn C.G., and Farde L. Quantification of [11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. Journal of Cerebral Blood Flow and Metabolism 19 (1999) 1164-1173
54. Rimondini R., Fuxe K., and Ferre S. Multiple intramembrane receptor-receptor interactions in the regulation of striatal dopamine D2 receptors. NeuroReport 10 (1999) 2051-2054
55. Sareen J., Campbell D.W., Leslie W.D., Malisza K.L., Stein M.B., Paulus M.P., Kravetsky L.B., Kjernisted K.D., Walker J.R., and Reiss J.P. Striatal function in generalized social phobia: a functional magnetic resonance imaging study. Biological Psychiatry 61 (2007) 396-404
56. Schneier F.R., Liebowitz M.R., Abi-Dargham A., Zea-Ponce Y., Lin S.-H., and Laruelle M. Low dopamine D2 receptor binding potential in social phobia. American Journal of Psychiatry 157 (2000) 457-459
57. Seeman P., Schwarz J., Chen J.F., Szechtman H., Perreault M., McKnight G.S., Roder J.C., Quirion R., Boksa P., Srivastava L.K., Yanai K., Weinshenker D., and Sumiyoshi T. Psychosis pathways converge via D2 high dopamine receptors. Synapse 60 (2006) 319-346
58. Slifstein M., and Laruelle M. Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nuclear Medicine and Biology 28 (2001) 595-608
59. Tiihonen J., Kuikka J., Bergström K., Lepola U., Koponen H., and Leinonen E. Dopamine reuptake site densities in patients with social phobia. American Journal of Psychiatry 154 (1997) 239-242
60. Tiihonen J., Kuikka J., Räsänen P., Lepola U., Koponen H., Liuska A., Lehmusvaara A., Vainio P., Könönen M., Bergström K., Yu M., Kinnunen I., Åkerman K., and Karhu J. Cerebral bezodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis. Molecular Psychiatry 2 (1997) 463-471
61. Tsukada H., Nishiyama S., Fukumoto D., Sato K., Kakiuchi T., and Domino E.F. Chronic NMDA antagonism impairs working memory, decreases extracellular dopamine, and increases D1 receptor binding in prefrontal cortex of conscious monkeys. Neuropsychopharmacology 30 (2005) 1861-1869
62. van Kammen D.P. Gamma-aminobutyric acid (GABA) and the dopamine hypothesis of schizophrenia. American Journal of Psychiatry 134 (1977) 138-143
63. Vilkman H., Kajander J., Någren K., Oikonen V., Syvälahti E., and Hietala J. Measurement of extrastriatal D2-like receptor binding with [11C] FLB 457 - a test-retest analysis. European Journal of Nuclear Medicine 27 (2000) 1666-1673
64. Vivo M., Lin H., and Strange P.G. Investigation of cooperativity in the binding of ligands to the D(2) dopamine receptor. Molecular Pharmacology 69 (2006) 226-235
65. Volkow N.D., Wang G.J., Hitzemann R., Fowler J.S., Pappas N., Lowrimore P., Burr G., Pascani K., Overall J., and Wolf A.P. Depression of thalamic metabolism by lorazepam is associated with sleepiness. Neuropsychopharmacology 12 (1995) 123-132
66. Wang G.J., Volkow N.D., Overall J., Hitzemann R.J., Pappas N., Pascani K., and Fowler J.S. Reproducibility of regional brain metabolic responses to lorazepam. Journal of Nuclear Medicine 37 (1996) 1609-1613
67. Wang G.J., Volkow N.D., Fowler J.S., Hitzemann R.J., Pappas N.R., and Netusil N. Evaluation of gender difference in regional brain metabolic responses to lorazepam. Psychiatry Research 82 (1998) 37-46
68. Waszczak B.L., and Walters J.R. Effects of GABAergic drugs on single unit activity of A9 and A10 dopamine neurons. Brain Research Bulletin 5 suppl. 2 (1980) 465-470
69. Waszczak B.L., and Walters J.R. Intravenous GABA agonist administration stimulates firing of A10 dopaminergic neurons. European Journal of Pharmacology 66 (1980) 141-144
70. Zhou Y., Brasic J.R., Ye W., Dogan A.S., Hilton J., Singer H.S., and Wong D.F. Quantification of cerebral serotonin binding in normal controls and subjects with Tourette's syndrome using [11C]MDL 100,907 and (+)[11C]McN 5652 dynamic PET with parametric imaging approach. NeuroImage 22 suppl. 2 (2004) T98-T99